Your browser doesn't support javascript.
loading
Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease.
O'Donoghue, Michelle L; Giugliano, Robert P; Wiviott, Stephen D; Atar, Dan; Keech, Anthony; Kuder, Julia F; Im, KyungAh; Murphy, Sabina A; Flores-Arredondo, Jose H; López, J Antonio G; Elliott-Davey, Mary; Wang, Bei; Monsalvo, Maria Laura; Abbasi, Siddique; Sabatine, Marc S.
Afiliação
  • O'Donoghue ML; TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (M.L.O., R.P.G., S.D.W., J.F.K., K.I., S.A.M., M.S.S.).
  • Giugliano RP; TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (M.L.O., R.P.G., S.D.W., J.F.K., K.I., S.A.M., M.S.S.).
  • Wiviott SD; TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (M.L.O., R.P.G., S.D.W., J.F.K., K.I., S.A.M., M.S.S.).
  • Atar D; Department of Cardiology, Oslo University Hospital Ulleval, Norway (D.A.).
  • Keech A; Institute of Clinical Medicine, University of Oslo, Norway (D.A.).
  • Kuder JF; TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (M.L.O., R.P.G., S.D.W., J.F.K., K.I., S.A.M., M.S.S.).
  • Im K; TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (M.L.O., R.P.G., S.D.W., J.F.K., K.I., S.A.M., M.S.S.).
  • Murphy SA; TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (M.L.O., R.P.G., S.D.W., J.F.K., K.I., S.A.M., M.S.S.).
  • Flores-Arredondo JH; TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (M.L.O., R.P.G., S.D.W., J.F.K., K.I., S.A.M., M.S.S.).
  • López JAG; Global Development, Amgen, Thousand Oaks, CA (J.H.F.-A., J.A.G.L., B.W., M.L.M., S.A.).
  • Elliott-Davey M; Global Development, Amgen, Thousand Oaks, CA (J.H.F.-A., J.A.G.L., B.W., M.L.M., S.A.).
  • Wang B; Amgen Ltd, Cambridge, United Kingdom (M.E.-D.).
  • Monsalvo ML; Global Development, Amgen, Thousand Oaks, CA (J.H.F.-A., J.A.G.L., B.W., M.L.M., S.A.).
  • Abbasi S; Global Development, Amgen, Thousand Oaks, CA (J.H.F.-A., J.A.G.L., B.W., M.L.M., S.A.).
  • Sabatine MS; Global Development, Amgen, Thousand Oaks, CA (J.H.F.-A., J.A.G.L., B.W., M.L.M., S.A.).
Circulation ; 146(15): 1109-1119, 2022 10 11.
Article em En | MEDLINE | ID: mdl-36031810
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Cardiovasculares / Inibidores de Hidroximetilglutaril-CoA Redutases / Acidente Vascular Cerebral / Aterosclerose / Anticolesterolemiantes / Infarto do Miocárdio Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Revista: Circulation Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Cardiovasculares / Inibidores de Hidroximetilglutaril-CoA Redutases / Acidente Vascular Cerebral / Aterosclerose / Anticolesterolemiantes / Infarto do Miocárdio Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Revista: Circulation Ano de publicação: 2022 Tipo de documento: Article